{
    "clinical_study": {
        "@rank": "147862", 
        "arm_group": [
            {
                "arm_group_label": "Raltegravir Film-coated Tablet", 
                "arm_group_type": "Experimental", 
                "description": "Raltegravir 400 mg administered orally twice daily (b.i.d.)"
            }, 
            {
                "arm_group_label": "Raltegravir Chewable Tablet", 
                "arm_group_type": "Experimental", 
                "description": "Raltegravir administered b.i.d. at a weight-based dose not to exceed 300 mg b.i.d."
            }
        ], 
        "brief_summary": {
            "textblock": "This multicenter, open-label, noncomparative study evaluates two oral formulations of\n      raltegravir (MK-0518) in combination with other antiretroviral agents for safety,\n      tolerability, and antiretroviral activity in treatment-inexperienced or\n      treatment-experienced Russian children and adolescents infected with human immunodeficiency\n      virus-1 (HIV-1).\n\n      As raltegravir is indicated in combination with other antiretroviral therapies (ARTs) for\n      the treatment of HIV-1 infection in pediatric patients in the United States (US), this study\n      is designed to gain local treatment experience on the use\n\n      of raltegravir in the pediatric HIV-infected population in Russia."
        }, 
        "brief_title": "A Study of the Safety, Tolerability, and Antiretroviral Activity of Raltegravir (MK-0518) in Combination With Other Antiretroviral Therapies in Russian Children and Adolescents Infected With HIV-1", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "HIV Infection", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  HIV positive\n\n          -  Weight of at least 7 kg\n\n          -  HIV RNA \u22651000 copies/mL within 45 days before study treatment\n\n          -  Participants of reproductive potential and sexually active agree to remain\n\n        abstinent or use (or have their partner use) an acceptable method of birth control\n        throughout the study.\n\n        Exclusion Criteria:\n\n          -  Females pregnant or breast-feeding, or expecting to conceive or donate eggs\n\n        during the study; males planning to impregnate or provide sperm donation\n\n        during the study\n\n          -  Use of any non-antiretroviral (ART) investigational agents within one month before\n             study treatment\n\n          -  Current (active) diagnosis of acute hepatitis or chronic hepatitis other than stable\n             chronic Hepatitis B and/or C\n\n          -  Prior or current use of raltegravir\n\n          -  Use of another experimental HIV-integrase inhibitor\n\n          -  History or current evidence of any condition, therapy, laboratory\n\n        abnormality, or other circumstance that might confound the results of the study, or\n        interfere with participation for the full duration of the study\n\n          -  Requires or is anticipated to require any prohibited medications\n\n          -  Use of immunosuppressive therapy within 30 days before beginning\n\n        raltegravir study treatment; short courses of corticosteroids are permitted.\n\n          -  History of malignancy\n\n          -  Current treatment for active tuberculosis infection\n\n          -  Use of recreational or illicit drugs or a recent history (within the\n\n        last year) of drug or alcohol abuse or dependence"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01717287", 
            "org_study_id": "0518-248"
        }, 
        "intervention": [
            {
                "arm_group_label": "Raltegravir Film-coated Tablet", 
                "description": "Raltegravir 400 mg film-coated tablet orally b.i.d.", 
                "intervention_name": "Raltegravir Film-coated Tablet", 
                "intervention_type": "Drug", 
                "other_name": [
                    "ISENTRESS\u00ae", 
                    "MK-0518"
                ]
            }, 
            {
                "arm_group_label": "Raltegravir Chewable Tablet", 
                "description": "Raltegravir chewable tablet orally b.i.d. at a dose not to exceed 300 mg b.i.d.", 
                "intervention_name": "Raltegravir Chewable Tablet", 
                "intervention_type": "Drug", 
                "other_name": [
                    "ISENTRESS\u00ae", 
                    "MK-0518"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Anti-Retroviral Agents"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "December 30, 2013", 
        "number_of_arms": "2", 
        "official_title": "A Phase II, Multicenter, Open-Label, Noncomparative Study of Raltegravir (MK-0518) in Two Oral Formulations in Combination With Other Antiretroviral Agents to Evaluate the Safety, Tolerability, and Antiretroviral Activity in HIV-1 Infected Russian Children and Adolescents", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Russia: Ministry of Health of the Russian Federation", 
                "Russia: Ethics Committee"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Percentage of Participants With at Least One Adverse Experience (AE)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 26 Weeks"
            }, 
            {
                "measure": "Percentage of Participants who Discontinued Study Treatment due to AEs", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 24 Weeks"
            }
        ], 
        "removed_countries": {
            "country": "Russian Federation"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01717287"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of Participants Achieving \u22651 Log^10 Reduction from Baseline in Human Immunodeficiency Virus (HIV) Ribonucleic Acid (RNA) or HIV RNA <200 copies/mL", 
                "safety_issue": "No", 
                "time_frame": "24 Weeks"
            }, 
            {
                "measure": "Percentage of Participants Achieving HIV RNA <40 copies/mL", 
                "safety_issue": "No", 
                "time_frame": "24 Weeks"
            }, 
            {
                "measure": "Percentage of Participants Achieving HIV RNA <200 copies/mL", 
                "safety_issue": "No", 
                "time_frame": "24 Weeks"
            }, 
            {
                "measure": "Change from Baseline in Cluster of Differentiation 4 (CD4) Cell Count (cells/mm^3)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 24 Weeks"
            }, 
            {
                "measure": "Change from Baseline in CD4 Percent", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 24 Weeks"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}